BioCentury
ARTICLE | Strategy

Sticking to core values

February 5, 2007 8:00 AM UTC

Novo Nordisk A/S is dropping small molecules in order to focus on turning its mature biologics franchise into an engine for growth and diversification. By returning to its recombinant protein roots, the company hopes to protect its dominant diabetes care franchise, expand its growth disorder and hemostasis businesses, and establish a position in inflammatory diseases and oncology.

While the other big players in diabetes are pursuing newly commercialized targets and partnering with biotechs to pursue more novel approaches, NVO (Bagsvaerd, Denmark) is counting on its existing diabetes franchise to continue to drive double-digit annual overall sales growth (see "New Treatment Landscape," A2 & "New Diabetes Targets," A3). ...